There are many options to treat myelodysplastic syndromes, or MDS. Treatment for MDS may help improve your quality of life and help you live a longer and more normal life.
In this video, learn about the treatment options for MDS, according to Jonathan Feld, MD, Hematology Specialist at The Mount Sinai Hospital in New York City.
Jonathan Feld, MD, is a hematology specialist at The Mount Sinai Hospital.
References
American Cancer Society. (2016). Blood transfusions for people with cancer.
American Cancer Society. (2018). General approach to treatment of myelodysplastic syndromes.
American Cancer Society. (2018). Stem cell transplant for myelodysplastic syndrome.
Bristol Myers Squibb. (2020). U.S. Food and Drug Administration (FDA) approves Reblozyl (luspatercept-aamt), the first and only erythroid maturation agent, to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS).
National Cancer Institute. (2023). Myelodysplastic syndromes treatment (PDQ) - patient version.
Schoener, B., et al. (2023). Erythropoietin stimulating agents. StatPearls.
Why trust our experts?
